| Avonex (recombinant IFN-β-1a) / Biogen |
| Not yet recruiting | 4 | 90 | | | Biogen Idec Australia Pty Ltd, Biogen Idec Australia Pty Ltd | Multiple Sclerosis | | | | |
NCT00037115: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. |
|
|
| Withdrawn | 4 | 0 | US | interferon beta 1a, methotrexate, methylprednisolone | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute, Consultants in Neurology | Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis | 12/02 | 12/02 | | |
| Completed | 4 | 408 | US | Interferon beta-1a (Avonex), Avonex | Biogen | Multiple Sclerosis | 06/03 | 07/03 | | |
NCT00037102: Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis |
|
|
| Completed | 4 | 16 | NA | interferon beta 1a, methotrexate | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute, Consultants in Neurology, Biogen | Multiple Sclerosis | 12/03 | 12/03 | | |
FLAIR, NCT00534261: Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? |
|
|
| Completed | 4 | 284 | Europe | Interferon beta-1a | Biogen | Relapsing Remitting Multiple Sclerosis | | 02/04 | | |
NCT00913666: Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers |
|
|
| Completed | 4 | 121 | US | Interferon beta-1a (Avonex), Avonex | Biogen | Multiple Sclerosis | | 11/04 | | |
NCT00206648: An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS |
|
|
| Completed | 4 | 271 | US, Canada | Betaferon/Betaseron | Bayer | Multiple Sclerosis, Relapsing-Remitting | | 10/05 | | |
SAFE, NCT00493077: Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy |
|
|
| Completed | 4 | 3 | Europe | low immunogenic interferon-beta-1a, Avonex | Biogen | Multiple Sclerosis | 05/06 | 05/06 | | |
| Completed | 4 | 350 | US | Methotrexate, IV methylprednisolone | Biogen | Multiple Sclerosis, Relapsing-Remitting | 06/06 | 05/07 | | |
RECOVER, NCT00492466: Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies |
|
|
| Completed | 4 | 14 | Europe | Interferon-beta-1a, Avonex, methylprednisolone | Biogen | Relapsing-Remitting Multiple Sclerosis | 08/06 | 08/06 | | |
NCT00146068: EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis |
|
|
| Completed | 4 | 30 | US | Avonex/Zocor | University of North Carolina | Multiple Sclerosis | 12/07 | 12/07 | | |
TODAY, NCT00574041: How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose |
|
|
| Terminated | 4 | 19 | RoW | Interferon beta-1a, Avonex | Biogen | Relapsing Remitting Multiple Sclerosis | 02/08 | 02/08 | | |
NCT00168766: Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS |
|
|
| Completed | 4 | 345 | Europe | Interferon-beta-1a (Avonex) plus methylprednisolone, Avonex | Biogen | Relapsing-remitting Multiple Sclerosis | 11/08 | 11/08 | | |
| Completed | 4 | 155 | US, Canada | interferon beta 1a 30 ug IM once weekly | Beth Israel Deaconess Medical Center, Biogen | Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome | 03/09 | 03/09 | | |
|
NCT00246324: Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis |
|
|
| Completed | 4 | 16 | US | Interferon beta 1a, oral doxycycline, Avonex | Louisiana State University Health Sciences Center Shreveport, Biogen | Multiple Sclerosis | 08/09 | 10/09 | | |
PRTOECT, NCT00771043: A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a |
|
|
| Withdrawn | 4 | 50 | NA | TYSABRI and AVONEX | Biogen | Relapsing-remitting Multiple Sclerosis | 08/09 | 06/10 | | |
RENeu, NCT00493116: Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta |
|
|
| Completed | 4 | 20 | RoW | Interferon-beta-1a, Avonex, methylprednisolone | Biogen | Relapsing-Remitting Multiple Sclerosis | 12/09 | 12/09 | | |
| Completed | 4 | 380 | Europe | Interferon-beta-1a, Avonex, Simvastatin, Placebo | Biogen | Multiple Sclerosis | 04/10 | 04/10 | | |
|
EPOC, NCT01216072: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis |
|
|
| Completed | 4 | 1053 | US, Canada | Fingolimod, GILENYA™, Standard MS DMTs, Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia® | Novartis Pharmaceuticals | Relapsing Forms of Multiple Sclerosis | 08/12 | 08/12 | | |
|
|
|
|
NCT00101959: Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects |
|
|
| Withdrawn | 4 | 0 | US | Rebif | EMD Serono | Relapsing-Remitting Multiple Sclerosis | | | | |
| Completed | 4 | 61 | Europe | Fingolimod, GILENYA™, Standard MS DMT, Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia® | Novartis Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 06/14 | 06/14 | | |
2011-001956-12: Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis |
|
|
| Completed | 4 | 85 | Europe | Avonex®, Betaferon®, Rebif 22®, Rebif 44®, Extavia®, EU/1/97/033/002, EU/1/95/003/005-010, EU/1/98/063/001-003, EU/1/98/063/004-006, EU/1/08/454/001-002, EU/1/08/454/005-007, Injection, Avonex®, Betaferon®, Rebif 22®, Rebif 44®, Extavia® | University Hospital Motol | To correlate bioactivity of IFNβ reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNβ depending on NAbs status NAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested., Biological efficacy of IFNβ treatment in patiens with multiple sclerosis will be tested with the MxA protein,which will be detected in the blood. | | | | |
2005-001281-13: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study) |
|
|
| Completed | 4 | 220 | Europe | Avonex, Interferonum beta-1a, AVONEX, AVONEX | DSC Services, s.r.o. | Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms) | | 01/14 | | |
2009-017003-28: Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m. Open label multicentre study |
|
|
| Completed | 4 | 174 | Europe | AVONEX, AVONEX | BIOGEN-DOMPE, SRL | multiple sclerosis | | | | |
| Ongoing | 4 | 60 | Europe | beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada | Turku University Hospital, Novartis Pharma | Multiple sclerosis MS-tauti | | | | |
2012-005450-30: Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy Erforschung der Bildung neutralisierender Antikörper gegen Interferon-beta bei Patienten mit Multipler Sklerose. Ziel ist es, Faktoren zu finden, mit denen man die Ausbildung solcher Antikörper vorhersagen und damit das Risiko einer unwirksamen Therapie vermindern kann |
|
|
| Ongoing | 4 | 50 | Europe | Avonex, Rebif, Betaferon, Extavia, Avonex, Rebif, Betaferon, Extavia | Medizinische Universität Innsbruck, ABIRISK | Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis Entwicklung neutralisierender Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose | | | | |
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros. |
|
|
| Ongoing | 4 | 150 | Europe | Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio | Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10] | | | | |
2016-004819-12: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients Sclerosi Multipla: effetti della sospensione del trattamento protratto con farmaci immunomodulanti di prima linea in pazienti "full responders" |
|
|
| Ongoing | 4 | 300 | Europe | Interferone Beta-1B, Inteferone Beta-1A, Glatiramer acetato, Interferon Beta-1a, [032166011], [033283045], [035418060], [034091165], Powder and solvent for solution for injection, Solution for injection, BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML, AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE, COPAXONE - "40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA" 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO, REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | OSPEDALE SAN RAFFAELE, AIFA - Italian Medicines Agency | Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 4 | 800 | Europe, US | Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod) | The Cleveland Clinic, University of Nottingham | Multiple Sclerosis, Relapsing-Remitting | 04/30 | 09/30 | | |
